Insulin icodec offers a reduction in dosing frequency of injectable therapies to once weekly, which may improve convenience, adherence, and quality of life over once-daily basal insulin analogs. In this touchENDOCRINOLOGY interview, Prof. Chantal Mathieu (University Hospital Gasthuisberg Leuven, Leuven, Belgium) discusses the limitations of once daily basal insulin analogues and gives an overview on insulin icodec.
The abstract entitled: ‘Once-Weekly Insulin Icodec vs Once-Daily Insulin Glargine U100 in Combination with Bolus Insulin in Individuals with Type 2 Diabetes on Basal-Bolus Regimens (ONWARDS 4)‘ was presented at the 22nd Annual Diabetes Technology Meeting, 03-05 Nov, 2022.
Questions:
- What are the limitations of once daily basal insulin analogues? (0:20)
- What is insulin icodec and what is the basis for its long half-life? (2:40)
Disclosures: Chantal Mathieu has received grant/research support from Medtronic, Imcyse, Novo Nordisk, Sanofi and ActoBio Therapeutics.
Support: Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.
Recorded as a highlight of DTM 2022
